Cognitive function in long-term testicular cancer survivors: impact of modifiable factors.

Loading...
Thumbnail Image

Embargo End Date

ICR Authors

Authors

Dinh, PC
Monahan, PO
Fung, C
Sesso, HD
Feldman, DR
Vaughn, DJ
Hamilton, RJ
Huddart, R
Martin, NE
Kollmannsberger, C
Althouse, S
Einhorn, LH
Frisina, R
Root, JC
Ahles, TA
Travis, LB

Document Type

Journal Article

Date

2024-09-02

Date Accepted

2024-08-07

Abstract

No study has comprehensively examined associated factors (adverse health outcomes, health behaviors, and demographics) affecting cognitive function in long-term testicular cancer survivors (TC survivors). TC survivors given cisplatin-based chemotherapy completed comprehensive, validated surveys, including those that assessed cognition. Medical record abstraction provided cancer and treatment history. Multivariable logistic regression examined relationships between potential associated factors and cognitive impairment. Among 678 TC survivors (median age = 46; interquartile range [IQR] = 38-54); median time since chemotherapy = 10.9 years, IQR = 7.9-15.9), 13.7% reported cognitive dysfunction. Hearing loss (odds ratio [OR] = 2.02; P = .040), neuropathic pain (OR = 2.06; P = .028), fatigue (OR = 6.11; P < .001), and anxiety/depression (OR = 1.96; P = .029) were associated with cognitive impairment in multivariable analyses. Being on disability (OR = 9.57; P = .002) or retired (OR = 3.64; P = .029) were also associated with cognitive decline. Factors associated with impaired cognition identify TC survivors requiring closer monitoring, counseling, and focused interventions. Hearing loss, neuropathic pain, fatigue, and anxiety/depression constitute potential targets for prevention or reduction of cognitive impairment in long-term TC survivors.

Citation

JNCI Cancer Spectrum, 2024, 8 (5), pp. pkae068 -

Source Title

JNCI Cancer Spectrum

Publisher

OXFORD UNIV PRESS

ISSN

2515-5091

eISSN

2515-5091

Research Team

Clinic Acad RT Huddart

Notes